Skip to content

Clinical trials

Phase 1 Thyroid Cancer, Papillary trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Thyroid Cancer, Papillary Phase: Phase 1 Clear all

17 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20031
20042
20061
20072
20081
20101
20112
20182
20201
20221

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed13
Unknown status2
Terminated1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
European Organisation for Research and Treatment of Cancer - EORTC2
Exelixis2
National Cancer Institute (NCI)2
AHS Cancer Control Alberta1
Bezmialem Vakif University1
Lucille P. Markey Cancer Center at University of Kentucky1
Memorial Sloan Kettering Cancer Center1
Roswell Park Cancer Institute1
SWOG Cancer Research Network1
The First Affiliated Hospital of Xiamen University1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Thyroid Cancer, Papillary17
Thyroid Neoplasms11
Adenocarcinoma, Follicular10
Head and Neck Neoplasms6
Salivary Gland Neoplasms6
Carcinoma, Medullary5
Carcinoma, Non-Small-Cell Lung5
Colonic Neoplasms5
Squamous Cell Carcinoma of Head and Neck5
Thyroid Carcinoma, Anaplastic5

Trials

Showing 26 to 17 of 17. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.